Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy.
Berdeja JG et al. Br J Haematol. 2017 Feb 7. doi: 10.1111/bjh.14536. [Epub ahead of print].
Impact of induction treatment before autologous stem cell transplantation on long term outcome in patients with newly diagnosed multiple myeloma.
Gassiot S et al. Eur J Haematol. 2017 Feb 16. doi: 10.1111/ejh.12869. [Epub ahead of print].
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program.
Miyamoto T et al. Biol Blood Marrow Transplant. 2017 Feb 17. pii: S1083-8791(17)30281-1. doi: 10.1016/j.bbmt.2017.02.012. [Epub ahead of print].
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial.
Rosiñol L et al. Leukemia. 2017 Feb 14. doi: 10.1038/leu.2017.35. [Epub ahead of print].
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
Dimopoulos MA et al. Br J Haematol. 2017 Feb 17. doi: 10.1111/bjh.14549. [Epub ahead of print].
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.
Chng WJ et al. Leukemia. 2017 Feb 3. doi: 10.1038/leu.2016.390. [Epub ahead of print].
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 hour, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
Berenson J et al. Am J Hematol. 2017 Feb 18. doi: 10.1002/ajh.24687. [Epub ahead of print].
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
Quach H et al. Br J Haematol. 2017 Feb 15. doi: 10.1111/bjh.14562. [Epub ahead of print].
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Maciocia N et al. Br J Haematol. 2017 Feb 17. doi: 10.1111/bjh.14547. [Epub ahead of print].
Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
Conticello C et al. Future Oncol. 2017 Feb;13(5s):3-6. doi: 10.2217/fon-2016-0368.
Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Palmas A et al. Future Oncol. 2017 Feb;13(5s):7-9. doi: 10.2217/fon-2016-0460.